Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5

This study has been completed.
Sponsor:
Collaborator:
Cincinnati MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00015223
First received: April 18, 2001
Last updated: October 17, 2012
Last verified: October 2012
  Purpose

The purpose of this study is the use of Methylphenidate in the treatment of cocaine dependence and Attention Deficit Hyperactivity Disorder (ADHD) comorbidity.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Drug: Methylphenidate
Phase 2

Study Type: Interventional
Study Design: Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Methyphendidate in the Treatment of Cocaine Dependent Patients With Adult ADHD

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Cocaine use
  • Methylphenidate retention
  • Safety assessments
  • Psychosocial counseling sessions

Estimated Enrollment: 0
Study Start Date: June 1997
Detailed Description:

The objective of this study is to determine the safety and efficacy of methylphenidate in a population of patients who are cocaine dependent and suffer from attention deficit hyperactivity disorder.

  Eligibility

Ages Eligible for Study:   21 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Cocaine-dependent. Meets the DSM-IV criteria for ADHD. Actively using cocaine within the past 30 days of screening.

Exclusion Criteria:

Symptoms of AIDS. Significant medical disorder. DSM-IV criteria for any substance other than cocaine, alcohol, nicotine, marijuana, caffeine. Requires detoxification from ETOH or benzos. History of seizures.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00015223

Locations
United States, Ohio
Cincinnati MDRU
Cincinnati, Ohio, United States
Sponsors and Collaborators
Cincinnati MDRU
Investigators
Principal Investigator: Gene Somoza, M.D. U of Cincinnati
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00015223     History of Changes
Other Study ID Numbers: NIDA-5-0013-5, Y01-5-0013-5
Study First Received: April 18, 2001
Last Updated: October 17, 2012
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Attention Deficit Disorder with Hyperactivity
Mental Disorders
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Methylphenidate
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 20, 2014